PANoptosis emerges as critical programmed cell death mechanism in Alzheimer's disease pathogenesis, identifying therapeutic targets.
Background
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia, characterized by the accumulation of amyloid-β plaques and neurofibrillary tangles, leading to neurodegeneration and cognitive decline. Current treatments primarily manage symptoms, highlighting a critical need for therapies targeting underlying disease mechanisms. Emerging evidence identifies PANoptosis, a lytic form of programmed cell death, as a significant contributor to neuronal loss and pathology in AD, offering a novel therapeutic avenue beyond traditional amyloid and tau hypotheses.
Study Design
This comprehensive review synthesizes the current understanding of PANoptosis in the context of Alzheimer's disease. Researchers systematically analyzed existing literature to delineate the intricate signaling pathways that regulate PANoptosis and its downstream effects on neuroinflammation and neuronal demise. The review also explores various preclinical therapeutic interventions aimed at modulating PANoptosis to mitigate AD progression, providing a landscape of potential drug targets and strategies.
Results
The review highlights that dysregulation of several key signaling pathways significantly contributes to PANoptosis in Alzheimer's disease. These include the cGAS-STING, PI3K/AKT, JAK/STAT/IRF1, and p38/ERK/JNK MAPK pathways. Activation of these pathways enhances inflammation, increases free radical generation, causes mitochondrial damage, leads to synaptic impairment, and disrupts the blood-brain barrier (BBB).
PANoptosis is identified as a critical lytic programmed cell death mechanism driving neurodegeneration in Alzheimer's disease through the dysregulation of multiple interconnected inflammatory and stress-response pathways. Preclinical studies have begun to explore compounds, such as celasterol, that modulate these pathways to inhibit PANoptosis, suggesting promising therapeutic strategies for AD. The intricate interplay of these mechanisms underscores the complexity of AD pathogenesis and the multifaceted nature of PANoptosis.
Key Findings
- Dysregulation of
cGAS-STING,PI3K/AKT,JAK/STAT/IRF1, andp38/ERK/JNK MAPKpathways contribute to PANoptosis in AD. - PANoptosis enhances inflammation, free radical generation, mitochondrial damage, synaptic impairment, and
BBBdisruption. - PANoptosis is a critical lytic programmed cell death mechanism driving neurodegeneration in Alzheimer's disease.
- Preclinical studies on compounds like celasterol are exploring PANoptosis modulation as a therapeutic strategy for AD.
Why It Matters
Understanding PANoptosis as a central mechanism in Alzheimer's disease significantly broadens the scope for developing new therapeutic interventions beyond current amyloid- and tau-centric approaches. Targeting PANoptosis pathways could offer a novel strategy to prevent or slow neurodegeneration and cognitive decline in AD patients. This review identifies specific signaling cascades like cGAS-STING and MAPK as actionable drug targets, potentially leading to the development of small molecules or biologics that inhibit this destructive cell death. While still in preclinical stages, this research lays the groundwork for future clinical trials, suggesting that modulating programmed cell death could revolutionize AD treatment protocols.
alzheimer's disease
panoptosis
neurodegeneration
programmed cell death
inflammation
oxidative stress